The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315l mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide, that inhibits the T315l mutation in BCR-ABL tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.本發明關於治療對象之慢性骨髓性白血病的方法，其包含投予該對象抑制BCR-ABL酪胺酸激酶之T315l突變的化合物，諸如N-甲基-2-[3-((E)-2-吡啶-2-基-乙烯基)-1H-吲唑-6-基氫硫基]-苯甲醯胺或其藥學上可接受之鹽。本發明亦關於包含抑制BCR-ABL酪胺酸激酶之T315l突變的化合物，諸如N-甲基-2-[3-((E)-2-吡啶-2-基-乙烯基)-1H-吲唑-6-基氫硫基]-苯甲醯胺或其藥學上可接受之鹽以及藥學上可接受之載體或稀釋劑的醫藥組成物。
